Related Experiment Videos
Rhenium-188(Sn)HEDP for treatment of osseous metastases
H R Maxon1, L E Schroder, L C Washburn
1Department of Radiology, University of Cincinnati Medical Center, Ohio 45267-0577, USA.
Summary
Rhenium-188 (tin) hydroxyethylidine diphosphonate [188Re(Sn)HEDP] shows promise for treating skeletal metastases. This radiopharmaceutical allows for same-day, outpatient therapy with minimal radiation exposure to others.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical therapy
- Oncology
Background:
- Rhenium-188 (tin) hydroxyethylidine diphosphonate [188Re(Sn)HEDP] is a novel radiopharmaceutical designed for skeletal metastases.
- It emits beta particles with potential therapeutic benefits for patients with bone cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of 188Re(Sn)HEDP for treating skeletal metastases.
- To assess the feasibility of same-day, on-demand outpatient therapy using this agent.
Main Methods:
- In vitro and in vivo testing in laboratory, animal, and human studies.
- Production of 188Re(Sn)HEDP using various 188Re sources, including neutron irradiation and a 188W/188Re generator.
- Evaluation of radiochemical yields and purity with a minimum of 100 microg of rhenium.
Main Results:
- Satisfactory radiochemical yields and purity were achieved with all tested production methods.
- Biodistribution and dosimetry of 188Re(Sn)HEDP are comparable to 186Re(Sn)HEDP, suggesting similar therapeutic benefits and toxicities.
- Therapeutic doses of 188Re(Sn)HEDP result in low external radiation exposure rates from patients.
Conclusions:
- 188Re(Sn)HEDP is a viable option for same-day, on-demand outpatient therapy of disseminated skeletal metastases.
- The radiopharmaceutical demonstrates favorable safety and efficacy profiles for palliative care in oncology.